Furthermore, a therapeutic kinase inhibitor directed against all three novel targets, FLT3, BTK, and AURK, may be able to achieve much enhanced anti-leukemia efficacy in the targeted therapy of AML. Here, BTK is linked to acute myeloid leukemia.